focus -WSS

focus

author：knowledge 2025-09-29 22:51:58 - browse：88

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： A look at other Americans who have crossed into North Korea over the years

hotspot

WSS

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

BridgeBio heart drug succeeds in pivotal study

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

Democratic lawmaker calls for 'well

Study: Hearing aids may slow cognitive decline in those at risk

A look at other Americans who have crossed into North Korea over the years

Wikipedia

focus

leisure time

What does generative AI mean for health care? We asked experts

Manchin plays down potential 3rd

Novavax promises a turnaround & Lilly roils the obesity market

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

In age of alternative facts, a scholarly course on calling out crap

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

Medical records are filled with copy

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

United colonoscopy coverage change 'may cost lives,' doctors say

Mississippi candidates for statewide offices square off in party primaries

focus

Moderna hits safety problems in bold bid to reinvent medicine

What we know about the American soldier detained in North Korea

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

A look at other Americans who have crossed into North Korea over the years

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

FDA seeking to stop procedures at two unregulated stem cell clinics

leisure time

hotspot

hotspot

leisure time